Ladder Bio
PrivateLast Round
Seed
Nov 12, 2025
Total Funding Raised
$5.5M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Ladder Bio is a biotechnology company developing Spiroligomer™ molecules, a novel therapeutic modality for targeted drug discovery.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ladder Bio Comparables
Compare Ladder Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Insamo | 86% | |
| Vilya | 82% | |
| Unnatural Products | 77% | |
Ladder Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Nov 12, 2025 |
Ladder Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Medical Excellence Capital | Seed |
| Hatch Biofund | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 20, 2026
Monthly visitors grew 36% MoM, reaching 1.5K.
- Nov 12, 2025
$5.5M raised in Seed round.
Ladder Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Ladder Bio's valuation, stock price, and market status.